Literature DB >> 15300260

A simple method to cure established tumors by inflammatory killing of normal cells.

Gregory A Daniels1, Luis Sanchez-Perez, Rosa Maria Diaz, Timothy Kottke, Jill Thompson, Maoyi Lai, Michael Gough, Mahzuz Karim, Andrew Bushell, Heung Chong, Alan Melcher, Kevin Harrington, Richard G Vile.   

Abstract

We describe a simple technology used to cure an established metastatic disease. Intradermal injection of plasmid DNA encoding a transcriptionally targeted cytotoxic gene, along with hsp70, not only promoted tissue-specific, inflammatory killing of normal melanocytes, but also induced a CD8(+) T-cell-dependent, antigen-specific response in mice that eradicated systemically established B16 tumors. This CD8(+) T cell response was subsequently suppressed in vivo within a few days. The data demonstrate that deliberate destruction of normal tissue can be exploited to generate immunity against a malignant disease originating from that tissue. This approach obviates the need to identify tumor antigens and does not require complex isolation of tumor cells or their derivatives. In addition, it provides a model system for studying the mechanisms underlying the etiology and control of autoimmune diseases. Finally, despite targeting normal tissue, therapy could be separated from development of overt autoimmune symptoms, suggesting that the strategy may be valuable against tumors derived from both non-essential and essential tissue types.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300260     DOI: 10.1038/nbt1007

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  47 in total

Review 1.  Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.

Authors:  Ayesha Murshid; Jianlin Gong; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Expert Rev Vaccines       Date:  2011-11       Impact factor: 5.217

Review 2.  CD4 T cells in tumor immunity.

Authors:  Mara Gerloni; Maurizio Zanetti
Journal:  Springer Semin Immunopathol       Date:  2005-03-15

3.  Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.

Authors:  Yangbing Zhao; Zhili Zheng; Hung T Khong; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2006 Jul-Aug       Impact factor: 4.456

4.  A viral strategy to ambush tumors.

Authors:  Christopher Alvarez-Breckenridge; E Antonio Chiocca
Journal:  Nat Med       Date:  2011-07-07       Impact factor: 53.440

5.  Heat shock proteins in extracellular signaling.

Authors:  Stuart K Calderwood
Journal:  Methods       Date:  2007-11       Impact factor: 3.608

6.  Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Authors:  Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Authors:  Luis A Sanchez-Perez; Bryan D Choi; Gary E Archer; Xiuyu Cui; Catherine Flores; Laura A Johnson; Robert J Schmittling; David Snyder; James E Herndon; Darell D Bigner; Duane A Mitchell; John H Sampson
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

8.  Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Authors:  Timothy Kottke; Rosa M Diaz; Karen Kaluza; Jose Pulido; Feorillo Galivo; Phonphimon Wongthida; Jill Thompson; Candice Willmon; Glen N Barber; John Chester; Peter Selby; Scott Strome; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

9.  Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer.

Authors:  Michael R Shurin; Alla I Potapovich; Yulia Y Tyurina; Irina L Tourkova; Galina V Shurin; Valerian E Kagan
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

10.  Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Authors:  Feorillo Galivo; Rosa Maria Diaz; Uma Thanarajasingam; Dragan Jevremovic; Phonphimon Wongthida; Jill Thompson; Timothy Kottke; Glen N Barber; Alan Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.